积分剂量或平均剂量预测三叉神经痛患者放射外科反应:提议靶向神经最窄处
本研究纳入94例首次接受立体定向放射外科(SRS)的1型三叉神经痛患者,外部验证积分剂量(ID)对预后的预测价值。中位随访14.4个月,90%患者获得显著疼痛缓解;ID与初始疼痛缓解、疼痛复发及感觉功能障碍均无显著关联。多因素分析显示神经平均剂量≥65 Gy与疼痛复发风险降低相关(HR 0.408,P=0.039)。
要点
- 积分剂量(ID)未能预测无复发生存或感觉功能障碍。
- 神经平均剂量≥65 Gy与疼痛复发风险降低相关(HR 0.408,P=0.039)。
- 21%患者出现感觉功能障碍,3%需进一步药物治疗。
核心结论
- 积分剂量(ID)未能预测无复发生存或感觉功能障碍。
- 作者认为,通过靶向更窄的神经段以改善等中心最强区域的神经覆盖,可能获得更持久的疼痛缓解。
- 需要进一步研究验证这些发现。
研究设计与样本
- 回顾性分析94例连续首次接受立体定向放射外科(SRS)的1型三叉神经痛患者,计算神经积分剂量(ID)。
- 处方剂量:70%为80 Gy,28%为85 Gy,2%为70 Gy。
主要发现
- 中位随访14.4个月,85例(90%)患者初次SRS后报告显著疼痛缓解(Barrow Neurological Institute I-III级)。
- 中位无疼痛复发生存期为82个月(95% CI 41.1-NA),1年、3年、5年估计值分别为80.5%、65.5%、55.9%。
- Cox比例风险模型显示,ID与初始疼痛缓解、疼痛复发风险或感觉功能障碍均无显著关联。
- 多因素分析显示,神经平均剂量≥65 Gy与疼痛复发风险降低相关(HR 0.408,P=0.039)。
- 20例(21%)患者SRS后出现感觉功能障碍,其中3例(3%)需进一步药物治疗;感觉功能障碍与处方剂量或脑干最大剂量无相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) is effective for patients with medically refractory trigeminal neuralgia with a 75%-90% response rate. Consideration of the integral dose (ID) to the target nerve within the 50% isodose line was reported to help select prescription doses to maximize effectiveness and minimize bothersome numbness. The objective of this study was to externally validate the ID as a predictor of outcomes after SRS. METHODS: We reviewed the outcomes and parameters of 94 consecutive patients of type 1 trigeminal neuralgia who had SRS for the first time where nerve ID was calculated. 70% of the prescription doses were 80 Gy, with 28% at 85 Gy, and 2% at 70 Gy. RESULTS: The median follow-up time was 14.4 months. A total of 85 (90%) patients reported significant pain relief (Barrow Neurological Institute I-III) after initial SRS. The median pain recurrence-free survival was 82 months (95% CI 41.1-NA), and estimates at 1, 3, and 5 years were 80.5%, 65.5%, and 55.9%, respectively. The ID was not significantly associated with initial pain relief, or affect the risk of pain recurrence or sensory dysfunction after SRS using the Cox proportional hazards model. A nerve mean dose ≥65 Gy was associated with a reduced risk of pain recurrence on multivariate analysis (hazard ratio 0.408, P = .039). Twenty (21%) patients experienced sensory dysfunction after SRS with 3 (3%) requiring further medications, which was not correlated with the prescription dose or brainstem maximum dose. CONCLUSION: The ID did not predict recurrence-free survival or sensory dysfunction. Our observations suggest improved nerve coverage by the most powerful area of the isocenter, for instance, by targeting a narrower segment if feasible, could result in more durable pain relief. Further studies to validate these findings are needed.
引用
- Meng Y, Santhumayor B, Mashiach E, et al. Integral Dose or Mean Dose for Predicting Radiosurgery Response in Patients With Trigeminal Neuralgia: A Proposal to Target the Narrowest Part of the Nerve. Neurosurgery. 2024. PMID: 39194227. doi:10.1227/neu.0000000000003145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。